The data from more than 56 million pregnancies was reviewed to examine links between elevated glucose levels and mental ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Full results will be presented on June 2025 at the American Diabetes Association (ADA) 85th Scientific Sessions and will be published in a peer-reviewed journal. Orforglipron is a once-daily ...

That three-pronged attack helped patients lose an average of about 24% of their body weight at 48 weeks in a phase 2 trial presented at the American Diabetes Association (ADA) congress.

Other ways to help manage your diabetes are described below. The ADA’s latest consensus report ... academic research institutions, and medical journals and associations. We only use quality ...

The American Diabetes Association (ADA) urged healthcare providers against ... therapy in children with growth hormone deficiency. (Journal of Clinical Endocrinology & Metabolism) In an emulated ...

Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in ...

According to the American Diabetes Association (ADA), these cholesterol amounts ... academic research institutions, and medical journals and associations. We only use quality, credible sources ...